Here are some updates on drug research and technology from my reading-
Window for administering medications to limit damage from stroke may be wider :
Medications to limit damage from a stroke by dissolving blood clots must be given within three hours of the event, according to standard guidelines. However, a research paper from The Lancet Neurology indicates that, this window of opportunity may extend to 4.5hours.
Researchers in Germany reached that conclusion after conducting a secondary analysis of "data from the third European Cooperative Acute Stroke Study," in which the "use of recombinant tissue plasminogen activator (rt-PA, alteplase)" was evaluated among 821 patients. Apparently, the results showed a clear benefit from treatment with alteplase in all types of patients, including those younger and older than 65 years, men and women, and those with or without a history of diabetes, stroke, or high blood pressure."
USFDA extends indication for Colchicine.
Medications to limit damage from a stroke by dissolving blood clots must be given within three hours of the event, according to standard guidelines. However, a research paper from The Lancet Neurology indicates that, this window of opportunity may extend to 4.5hours.
Researchers in Germany reached that conclusion after conducting a secondary analysis of "data from the third European Cooperative Acute Stroke Study," in which the "use of recombinant tissue plasminogen activator (rt-PA, alteplase)" was evaluated among 821 patients. Apparently, the results showed a clear benefit from treatment with alteplase in all types of patients, including those younger and older than 65 years, men and women, and those with or without a history of diabetes, stroke, or high blood pressure."
USFDA extends indication for Colchicine.
USFDA has extended the indication for the gout treatment and mediterranean fever drug Colchicine (Colcrys) to include prevention of acute gout flares. The drug, is the only single-ingredient colchicine product approved for prophylaxis and remedy of gout flares and its efficacy of the new indication is based on two randomized clinical trials. Patients in uric acid-lowering therapy were given 0.6 mg of colchicine twice daily, which decreased the frequency of gout.
Researchers say aldosterone antagonists only prescribed to one-third of heart failure patients.
Journal of the American Medical Association., reports that "most hospitalized heart failure patients are sent home without widely recommended inexpensive pills, despite a program to get more doctors to follow treatment guidelines. Just one-third of 12,565 patients eligible for the drugs, aldosterone antagonists, got them”.
Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
0 comments:
Post a Comment